CAS: 56442-17-2; 4-((4-Fluorobenzyl)Oxy)Benzaldehyde

上下游产品

4-hydroxy-benzaldehyde 1-chloromethyl-4-fluorobenzene 4-Fluorobenzyl bromide 4-hydroxy-benzoic acid α-[4-(4-fluorobenzyloxy)phenyl]-N-tert-butylnitrone (S)-N-(4-(4-fluorobenzyloxy)benzyl)-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-amine 5-(4-(4-fluorobenzyloxy)benzylidene)-2-thioxothiazolidin-4-one (4-(5-(1-(4-(4-fluorobenzyloxy)phenyl)methylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)acetic acid methyl ester

📜对羟基苯甲醛,4-氟溴苄置于potassium Carbonate体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,化学反应 12.0H,以65%的收率获得产物4-(4-氟苄氧基)苯甲醛
参考文献:发现针对150腔的高效选择性流感病毒神经氨酸酶抑制剂
标题:发现针对150腔的高效选择性流感病毒神经氨酸酶抑制剂
摘要:在我们较早发现n1选择性抑制剂的鼓舞下,可以进一步利用150腔流感病毒神经氨酸酶(nas)来产生更有效的奥司他韦衍生物.在这里,我们通过靶向150腔的奥司他韦的c 5-Nh 2结构修饰,报道了一系列新型奥司他韦衍生物的设计,合成和生物学评估.其中,带有4-(3-甲氧基苄氧基)苄基的化合物5C表现出最强的活性,它比奥司他韦羧酸盐(osc)对n1(h1N1),N1(h5N1)和n1(h5N1-H274Y)的活性低或适度提高).具体而言,针对野生型菌株h1N1的活性损失了30倍.但是5C与osc相比,其针对h5N1-H274Y Na的活性高4.85倍.同样,5C在体外显示出低细胞毒性,在小鼠中没有急性毒性.分子对接研究提供了对5C对n1和n1-H274Y突变型nas的高效力的见解.另外,对代表性化合物的理化性质和cyp酶抑制能力进行了计算机模拟预测,以评价其类药物性质.
DOI:10.1016/j.Ejmech.2020.113097

专利信息

专利号:WO-0053313-A2
优先权日:1999-03-09
标 题:Lanthanide catalysts for synthesis of compounds and combinatorial libraries

专利号:US-9423395-B2
优先权日:2013-01-14
标 题:Fluorescent cell cycle probe having M-phase specificity
发明人：CHANG YOUNG-TAE; ZHAI DUANTING; LEE SUNG-CHAN; YUN SEONG-WOOK; JEONG YUN-MI; KANG NAM-YOUNG; PARK SUNG-JIN
权利人:NAT UNIV SINGAPORE; AGENCY SCIENCE TECH & RES
摘要:The present invention is directed to a novel family of fluorophores based on the BODIPY scaffold, and methods for their synthesis. The BODIPY-based fluorophores disclosed herein are used for the selective visualization of cells that exist in the M-phase of the cell cycle. The present invention further relates to methods for the image-based monitoring of mitotic progression in live cells.